PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
24647557-4	2014	RESULTS: This is the largest reported cohort of AQP4-Ab positive patients treated with AZA.	Azathioprine	87-90	aquaporin 4	Homo sapiens	48-52	
29406904-7	2018	Compared with the AZA group, the MMF group and the RTX group decreased the AQP-4-IgG titre evidently and caused fewer adverse events.	Azathioprine	18-21	aquaporin 4	Homo sapiens	75-80	
34797551-8	2022	Meanwhile, the ARR also decreased in all AQP4-Ab groups (from 0.3 to 0.2 in RTX, from 0.9 to 0.5 in AZA, and from 0.9 to 0.4 in MMF).	Azathioprine	100-103	aquaporin 4	Homo sapiens	41-45	
34797551-14	2022	CONCLUSIONS: RTX, AZA, and MMF therapies efficiently lowered the relapse frequency and disability in both of the AQP4-Ab seropositive or seronegative patients with NMO.	Azathioprine	18-21	aquaporin 4	Homo sapiens	113-117	
27623738-4	2016	AZA is an antiepileptic drug that has been shown to inhibit AQP4 expression and in this study we investigate the drug as a therapeutic to mitigate the extent of mTBI induced cellular edema.	Azathioprine	0-3	aquaporin 4	Homo sapiens	60-64	
17178220-1	2007	Carbonic anhydrase inhibitors AZA, EZA, and 4-acetamidobenzsulfonamide were found to inhibit human AQP4-M23 mediated water transport by 80%, 68%, and 23%, respectively, at 20 microM in an in vitro functional assay.	Azathioprine	30-33	aquaporin 4	Homo sapiens	99-103	
17178220-2	2007	AZA was found to have an IC50 against AQP4 of 0.9 microM.	Azathioprine	0-3	aquaporin 4	Homo sapiens	38-42